Isala Klinieken Stichting

Research activity includes oncological immunotherapies with attention to treatment-related safety, particularly infusion-related reactions and hypersensitivity events associated with monoclonal antibodies.

• Infusion safety in cancer treatment
• Immune-mediated adverse reactions
• Monoclonal antibody tolerability

The clinical focus in this area is centered on adverse event monitoring during antineoplastic treatment.